Mycophenolate (Mycophenolate)
Overview of Mycophenolate
Mycophenolate is an immunosupressant, first isolated in 1898 from Penicillium stoloniferum. Mycophenolate is a reversible inhibitor of inosine monophosphate dehydrogenase and thus inhibits purine synthesis, with potent cytostatic effects on both T-and B-lymphocytes. Mycophenolate is used in combination with other immunosupressants, for the treatment and prevention of graft rejection and in auto-immune or immune-mediate inflammatory disease. it was approved by the FDA in May 3, 1995, for prevention of alograft rejection.,Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), belongs to a class of medications known as immunosuppressives. inosine monophosphate dehydrogenase (IMPDH) inhibitor. This medication was used originally in the management of patients with organ transplants, but is now recommended in the treatment of some autoimmune diseases.
Indication of Mycophenolate
Mycophenolate is primarily indicated in conditions like Graft rejection, Pophylaxis of acute renal transplant rejection, Pophylaxis of cardiac transplant rejection, Pophylaxis of hepatic transplant rejection, Symptoms associated with carcinoid tumours.
Contraindication of Mycophenolate
No data regarding the contra indications of Mycophenolate is available.
Side Effects of Mycophenolate
The severe or irreversible adverse effects of Mycophenolate, which give rise to further complications include Anemia, Anemia, Thrombocytopenia, Leucopenia, Bone marrow depression, Hyperglycemia, Hypertension, Hematuria, Tremors, Hyperglycemia, Anemia, Anemia, Disturbances of electrolyte, Disturbances of blood lipids.,The symptomatic adverse reactions produced by Mycophenolate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Alopecia, Diarrhea, Dyspnea, Insomnia, Pain, Cough, GI hemorrhage, GI disturbance, Alopecia, dizziness.
Precautions of Mycophenolate
It should be used with care in patients with severe renal impairment or active disorders of gastrointestinal tract. Therapy should begin as soon as possible after transplantation. Patient should undergo regular blood counts. If neutropenia develops than therapy should be stop or reducing the dose.